Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 35 of the 38 references it cites were found in a registry or an index; 22 of the 30 sources its claims cite were checked for support.

Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial

Open access

Abstract

The current third-line (and beyond) treatment options for RAS-mutant metastatic colorectal cancer have yielded limited efficacy. At the time of study start, the combination of sotorasib, a KRAS (Kirsten rat sarcoma viral oncogene homolog)-G12C inhibitor, and panitumumab, an epidermal growth factor receptor (EGFR) inhibitor, was hypothesized to overcome treatment-induced resistance. This phase 1b substudy of the CodeBreaK 101 master protocol evaluated sotorasib plus panitumumab in patients with chemotherapy-refractory KRASG12C-mutated metastatic colorectal cancer. Here, we report the results in a dose-exploration cohort and a dose-expansion cohort. Patients received sotorasib (960 mg, once daily) plus panitumumab (6 mg kg−1, once every 2 weeks). The primary endpoints were safety and tolerability. Secondary endpoints included efficacy and pharmacokinetics. Exploratory biomarkers at baseline were assessed. Forty-eight patients (dose-exploration cohort, n = 8; dose-expansion cohort, n = 40) were treated. Treatment-related adverse events of any grade and grade ≥3 occurred in 45 (94%) and 13 (27%) patients, respectively. In the dose-expansion cohort, the confirmed objective response rate was 30.0% (95% confidence interval (CI) 16.6%, 46.5%). Median progression-free survival was 5.7 months (95% CI 4.2, 7.7 months). Median overall survival was 15.2 months (95% CI 12.5 months, not estimable).

Overview

CoChat Summary

TL;DR

In this phase 1b CodeBreaK 101 substudy, sotorasib plus panitumumab was tolerable and showed promising efficacy in chemotherapy-refractory KRAS G12C-mutated metastatic colorectal cancer. Among 40 dose-expansion patients, confirmed ORR was 30.0%, median PFS 5.7 months, and median OS 15.2 months, with treatment-related grade ≥3 adverse events in 27% of all 48 patients.

Key findings

  • Safety: among 48 treated patients, treatment-related adverse events of any grade occurred in 45 (94%) and grade ≥3 in 13 (27%); there were no grade 4 or 5 treatment-related events and no treatment-related discontinuations. No dose-limiting toxicities were observed in the 7 evaluable dose-exploration patients.
  • Efficacy in the dose-expansion cohort (n=40): confirmed objective response rate 30.0% (95% CI 16.6–46.5), disease control rate 92.5% (95% CI 79.6–98.4), median duration of response 5.3 months (95% CI 2.8–7.4), median PFS 5.7 months (95% CI 4.2–7.7), and median OS 15.2 months (95% CI 12.5–not evaluable).
  • Dose-exploration cohort (n=8): 1 confirmed partial response (12.5%; 95% CI 0.3–52.7) and disease control rate 75.0% (95% CI 34.9–96.8); among 5 patients with prior sotorasib treatment, 80.0% achieved stable disease.
  • Baseline cfDNA alterations: most prevalent were APC (84%), TP53 (74%), SMAD4 (33%), PIK3CA (28%), and EGFR (26%). Median PFS was shorter with baseline BRAF alterations (2.9 vs 7.4 months) and ARID1A mutations (4.4 vs 7.4 months).

Methods

  • Design: phase 1b, multicenter, open-label substudy of the CodeBreaK 101 master protocol (subprotocol H, Part 1 Cohort A and Part 2 Cohort A), with a dose-exploration cohort (n=8) and dose-expansion cohort (n=40); enrollment occurred June 24, 2020–December 21, 2021, with data cutoff January 4, 2023.
  • Participants and treatment: adults with KRAS G12C-mutated metastatic colorectal cancer; dose-expansion patients had progression on or after fluoropyrimidine, oxaliplatin, irinotecan, and an antiangiogenic agent. Prior KRAS G12C inhibitor was permitted only in dose exploration. All patients received sotorasib 960 mg once daily plus panitumumab 6 mg/kg every 2 weeks.
  • Endpoints and analysis: primary endpoints were safety and tolerability (dose-limiting toxicities within 28 days and adverse events per CTCAE v5.0); secondary endpoints included ORR, DCR, duration of response, time to response, PFS, OS per RECIST v1.1 by investigator assessment, and pharmacokinetics. Exploratory baseline cfDNA was assessed with the 74-gene Guardant360 test. Descriptive statistics, Clopper-Pearson exact CIs, and Kaplan-Meier methods were used.

Limitations

  • Stated in the paper: this was a single-arm study; efficacy endpoints were based on investigator assessment rather than blinded independent central review; and the exploratory analysis of genomic co-alterations was not statistically powered.
  • Evident from the text: the sample size was small, subgroup analyses (e.g., BRAF/ARID1A alterations, tumor sidedness, region) had overlapping CIs, and the dose-exploration cohort was confounded by prior KRAS G12C inhibitor treatment in 5 of 8 patients.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02717-6

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

12 Valid · 3 Not valid · 6 Not checked · 72 Own results and interpretations

44 more claims

Create a free account to see all 93 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 30
  • It may state two separate claims as one. 19
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 38 references

Cited by

See all 103

Metadata

Authors
Kuboki, Y., Fakih, M., Strickler, J., Yaeger, R., Masuishi, T., Kim, E. J., Bestvina, C. M., Kopetz, S., Falchook, G. S., Langer, C., Krauss, J., Puri, S., Cardona, P., Chan, E., Varrieur, T., Mukundan, L., Anderson, A., Tran, Q., & Hong, D. S.
Affiliations
  • National Cancer Center Hospital East (JP)
  • City Of Hope National Medical Center (US)
  • Duke Medical Center (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Aichi Cancer Center Hospital (JP)
  • UC Davis Comprehensive Cancer Center (US)
  • University of Chicago (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Sarah Cannon (US)
  • University of Pennsylvania (US)
  • University of Michigan (US)
  • Huntsman Cancer Institute (US)
  • Amgen (United States) (US)
Corresponding author
Hong, David S.
Venue
Nature Medicine
Published
2024-01
Volume
30
Issue
1
Pages
265-270
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4390582065
Cited by
103
References
38
Citations by year
2026: 38 · 2025: 38 · 2024: 27
FWCI
17.53
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
Funders
Amgen
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
sotorasib, panitumumab, KRAS G12C mutation, metastatic colorectal cancer, chemotherapy-refractory disease, treatment resistance, objective response rate, progression-free survival, overall survival, safety and tolerability, pharmacokinetics, APC, TP53, SMAD4
MeSH terms
Panitumumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Humans, Mutation, Piperazines, Pyridines, Pyrimidines, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. https://app.cochat.ai/papers/10.1038/s41591-023-02717-6
The paper
Kuboki, Y., Fakih, M., Strickler, J., Yaeger, R., Masuishi, T., Kim, E. J., Bestvina, C. M., Kopetz, S., Falchook, G. S., Langer, C., Krauss, J., Puri, S., Cardona, P., Chan, E., Varrieur, T., Mukundan, L., Anderson, A., Tran, Q., & Hong, D. S. (2024). Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02717-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.